SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Results of Operations and Financial Condition

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02. Results of Operations and Financial Condition.

On March9, 2017, Sunesis Pharmaceuticals, Inc., or the Company,
reported its financial results for the three months and year
ended December31, 2016. A copy of the press release issued
concerning the foregoing results is furnished herewith as Exhibit
99.1 and is incorporated herein by reference.

The press release is furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or subject to the liabilities of that Section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained herein and in the accompanying
exhibit shall not be incorporated by reference into any filing
with the Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.


99.1 Press release, dated March9, 2017, entitled Sunesis
Pharmaceuticals Reports Fourth Quarter and Full-Year 2016
Financial Results and Recent Highlights.


Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.


SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) closed its last trading session up +0.07 at 4.37 with 44,360 shares trading hands.

An ad to help with our costs